Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism

Lisa Eggebrecht; Juergen H. Prochaska; Sven-Oliver Troebs; Soeren Schwuchow-Thonke; Sebastian Goebel; Simon Diestelmeier; Andreas Schulz; Natalie Arnold; Marina Panova-Noeva; Thomas Koeck; Steffen Rapp; Tommaso Gori; Karl J. Lackner; Hugo ten Cate; Thomas Muenzel; Philipp Sebastian Wild

doi:10.1007/s00392-018-1408-y

Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism

Lisa Eggebrecht, Juergen H. Prochaska, Sven-Oliver Troebs, Soeren Schwuchow-Thonke, Sebastian Goebel, Simon Diestelmeier, Andreas Schulz, Natalie Arnold, Marina Panova-Noeva, Thomas Koeck, Steffen Rapp, Tommaso Gori, Karl J. Lackner, Hugo ten Cate, Thomas Muenzel, Philipp Sebastian Wild^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BackgroundExperimental data indicate that direct acting oral anticoagulants (DOAC) and vitamin K antagonists (VKA) may exert differential effects on cardiovascular disease.MethodsData from the prospective, observational, single-center MyoVasc Study were used to examine associations of DOAC as compared to VKA with subclinical markers of cardiovascular disease, cardiac function, and humoral biomarkers in heart failure (HF).ResultsMultivariable analysis adjusted for age, sex, traditional cardiovascular risk factors, comorbidities, and medications with correction for multiple testing demonstrated that DOAC therapy was among all investigated parameters an independent significant predictor of better diastolic function (E/E: -0.24 [-0.36/-0.12]; P

Original language	English
Pages (from-to)	787-796
Number of pages	10
Journal	Clinical research in cardiology
Volume	108
Issue number	7
DOIs	https://doi.org/10.1007/s00392-018-1408-y
Publication status	Published - Jul 2019

Keywords

Anticoagulation
Direct oral anticoagulants
Vitamin K antagonist
Cardiac function
Lipids and lipid protein metabolism
DIRECT THROMBIN INHIBITION
FACTOR-XA
ATRIAL-FIBRILLATION
DABIGATRAN ETEXILATE
RIVAROXABAN
PROGRESSION
RISK
FIBROBLASTS
WARFARIN
DISEASE

Access to Document

10.1007/s00392-018-1408-y

Cite this

Eggebrecht, L., Prochaska, J. H., Troebs, S.-O., Schwuchow-Thonke, S., Goebel, S., Diestelmeier, S., Schulz, A., Arnold, N., Panova-Noeva, M., Koeck, T., Rapp, S., Gori, T., Lackner, K. J., ten Cate, H., Muenzel, T., & Wild, P. S. (2019). Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism. Clinical research in cardiology, 108(7), 787-796. https://doi.org/10.1007/s00392-018-1408-y

@article{b1d4dd9096f442e383d7685886b90a49,

title = "Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism",

abstract = "BackgroundExperimental data indicate that direct acting oral anticoagulants (DOAC) and vitamin K antagonists (VKA) may exert differential effects on cardiovascular disease.MethodsData from the prospective, observational, single-center MyoVasc Study were used to examine associations of DOAC as compared to VKA with subclinical markers of cardiovascular disease, cardiac function, and humoral biomarkers in heart failure (HF).ResultsMultivariable analysis adjusted for age, sex, traditional cardiovascular risk factors, comorbidities, and medications with correction for multiple testing demonstrated that DOAC therapy was among all investigated parameters an independent significant predictor of better diastolic function (E/E: -0.24 [-0.36/-0.12]; P",

keywords = "Anticoagulation, Direct oral anticoagulants, Vitamin K antagonist, Cardiac function, Lipids and lipid protein metabolism, DIRECT THROMBIN INHIBITION, FACTOR-XA, ATRIAL-FIBRILLATION, DABIGATRAN ETEXILATE, RIVAROXABAN, PROGRESSION, RISK, FIBROBLASTS, WARFARIN, DISEASE",

author = "Lisa Eggebrecht and Prochaska, {Juergen H.} and Sven-Oliver Troebs and Soeren Schwuchow-Thonke and Sebastian Goebel and Simon Diestelmeier and Andreas Schulz and Natalie Arnold and Marina Panova-Noeva and Thomas Koeck and Steffen Rapp and Tommaso Gori and Lackner, {Karl J.} and {ten Cate}, Hugo and Thomas Muenzel and Wild, {Philipp Sebastian}",

note = "Funding Information: Conflict of interest P.S.W., M.P.N., and J.H.P. are funded by the Federal Ministry of Education and Research (BMBF 01EO1503). P.S.W. has received research funding from Boehringer Ingelheim; PHILIPS Medical Systems; Sanofi-Aventis; Bayer Vital; Daiichi Sankyo Eu- rope; Federal Institute for Occupational Safety and Health (BAuA); Initiative {\textquoteleft}Health Economy{\textquoteright}, Ministry of Health and Ministry of Economics, Rhineland-Palatinate; Federal Ministry of Education and Research; Federal Ministry of Health, Rhineland-Palatinate (MSAGD); Mainz Heart Foundation; EU Grant agreement no. 278913, 278397 and received honoraria for lectures or consulting from Boehringer In-gelheim, Bayer HealthCare, Evonik, AstraZenca and Sanofi-Aventis. Funding Information: We gratefully thank all study participants and co-workers of the MyoVasc Study for their support and commitment. This work was supported by the German Center for Cardiovascular Research (DZHK) and the Center for Translational Vascular Biology (CTVB) of the University Medical Center of the Johannes Gutenberg-University Mainz. The sponsoring bodies played no role in the planning, conduct or analysis of the study. Funding Information: workers of the MyoVasc Study for their support and commitment. This work was supported by the German Center for Cardiovascular Research (DZHK) and the Center for Translational Vascular Biology (CTVB) of the University Medical Center of the Johannes Gutenberg-University Mainz. The sponsoring bodies played no role in the planning, conduct or analysis of the study. Publisher Copyright: {\textcopyright} 2019, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2019",

month = jul,

doi = "10.1007/s00392-018-1408-y",

language = "English",

volume = "108",

pages = "787--796",

journal = "Clinical research in cardiology",

issn = "1861-0684",

publisher = "Routledge/Taylor & Francis Group",

number = "7",

}

Eggebrecht, L, Prochaska, JH, Troebs, S-O, Schwuchow-Thonke, S, Goebel, S, Diestelmeier, S, Schulz, A, Arnold, N, Panova-Noeva, M, Koeck, T, Rapp, S, Gori, T, Lackner, KJ, ten Cate, H, Muenzel, T & Wild, PS 2019, 'Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism', Clinical research in cardiology, vol. 108, no. 7, pp. 787-796. https://doi.org/10.1007/s00392-018-1408-y

TY - JOUR

T1 - Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism

AU - Eggebrecht, Lisa

AU - Prochaska, Juergen H.

AU - Troebs, Sven-Oliver

AU - Schwuchow-Thonke, Soeren

AU - Goebel, Sebastian

AU - Diestelmeier, Simon

AU - Schulz, Andreas

AU - Arnold, Natalie

AU - Panova-Noeva, Marina

AU - Koeck, Thomas

AU - Rapp, Steffen

AU - Gori, Tommaso

AU - Lackner, Karl J.

AU - ten Cate, Hugo

AU - Muenzel, Thomas

AU - Wild, Philipp Sebastian

N1 - Funding Information: Conflict of interest P.S.W., M.P.N., and J.H.P. are funded by the Federal Ministry of Education and Research (BMBF 01EO1503). P.S.W. has received research funding from Boehringer Ingelheim; PHILIPS Medical Systems; Sanofi-Aventis; Bayer Vital; Daiichi Sankyo Eu- rope; Federal Institute for Occupational Safety and Health (BAuA); Initiative ‘Health Economy’, Ministry of Health and Ministry of Economics, Rhineland-Palatinate; Federal Ministry of Education and Research; Federal Ministry of Health, Rhineland-Palatinate (MSAGD); Mainz Heart Foundation; EU Grant agreement no. 278913, 278397 and received honoraria for lectures or consulting from Boehringer In-gelheim, Bayer HealthCare, Evonik, AstraZenca and Sanofi-Aventis. Funding Information: We gratefully thank all study participants and co-workers of the MyoVasc Study for their support and commitment. This work was supported by the German Center for Cardiovascular Research (DZHK) and the Center for Translational Vascular Biology (CTVB) of the University Medical Center of the Johannes Gutenberg-University Mainz. The sponsoring bodies played no role in the planning, conduct or analysis of the study. Funding Information: workers of the MyoVasc Study for their support and commitment. This work was supported by the German Center for Cardiovascular Research (DZHK) and the Center for Translational Vascular Biology (CTVB) of the University Medical Center of the Johannes Gutenberg-University Mainz. The sponsoring bodies played no role in the planning, conduct or analysis of the study. Publisher Copyright: © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2019/7

Y1 - 2019/7

N2 - BackgroundExperimental data indicate that direct acting oral anticoagulants (DOAC) and vitamin K antagonists (VKA) may exert differential effects on cardiovascular disease.MethodsData from the prospective, observational, single-center MyoVasc Study were used to examine associations of DOAC as compared to VKA with subclinical markers of cardiovascular disease, cardiac function, and humoral biomarkers in heart failure (HF).ResultsMultivariable analysis adjusted for age, sex, traditional cardiovascular risk factors, comorbidities, and medications with correction for multiple testing demonstrated that DOAC therapy was among all investigated parameters an independent significant predictor of better diastolic function (E/E: -0.24 [-0.36/-0.12]; P

AB - BackgroundExperimental data indicate that direct acting oral anticoagulants (DOAC) and vitamin K antagonists (VKA) may exert differential effects on cardiovascular disease.MethodsData from the prospective, observational, single-center MyoVasc Study were used to examine associations of DOAC as compared to VKA with subclinical markers of cardiovascular disease, cardiac function, and humoral biomarkers in heart failure (HF).ResultsMultivariable analysis adjusted for age, sex, traditional cardiovascular risk factors, comorbidities, and medications with correction for multiple testing demonstrated that DOAC therapy was among all investigated parameters an independent significant predictor of better diastolic function (E/E: -0.24 [-0.36/-0.12]; P

KW - Anticoagulation

KW - Direct oral anticoagulants

KW - Vitamin K antagonist

KW - Cardiac function

KW - Lipids and lipid protein metabolism

KW - DIRECT THROMBIN INHIBITION

KW - FACTOR-XA

KW - ATRIAL-FIBRILLATION

KW - DABIGATRAN ETEXILATE

KW - RIVAROXABAN

KW - PROGRESSION

KW - RISK

KW - FIBROBLASTS

KW - WARFARIN

KW - DISEASE

U2 - 10.1007/s00392-018-1408-y

DO - 10.1007/s00392-018-1408-y

M3 - Article

C2 - 30604046

SN - 1861-0684

VL - 108

SP - 787

EP - 796

JO - Clinical research in cardiology

JF - Clinical research in cardiology

IS - 7

ER -

Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism

Abstract

Keywords

Access to Document

Fingerprint

Cite this